58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial)
58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial)
The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
Key Inclusion Criteria:
Rollover participants are eligible for the study if they met the following inclusion criteria:
Key Exclusion criteria:
Rollover participants are excluded from the trial if any of the following met: